Literature DB >> 14587291

How serpins change their fold for better and for worse.

Robin W Carrell1, James A Huntington.   

Abstract

The serpins differ from the many other families of serine protease inhibitors in that they undergo a profound change in topology in order to entrap their target protease in an irreversible complex. The solving of the structure of this complex has now provided a video depiction of the changes involved. Cleavage of the exposed reactive centre of the serpin triggers an opening of the five-stranded A-sheet of the molecule, with insertion of the cleaved reactive loop as an additional strand in the centre of the sheet. The drastic displacement of the acyl-linked protease grossly disrupts its active site and gives an overall loss of 40% of ordered structure. This ability to provide effectively irreversible inhibition explains the selection of the serpins to control the proteolytic cascades of higher organisms. The conformational mechanism provides another advantage in its potential to modulate activity. Sequential crystallographic structures now provide clear depictions of the way antithrombin is activated on binding to the heparans of the microcirculation, and how evolution has utilized this mobile mechanism for subtle variations in activity. The complexity of these modulatory mechanisms is exemplified by heparin cofactor II, where the change in fold is seen to trigger multiple allosteric effects. The downside of the mobile mechanism of the serpins is their vulnerability to aberrant intermolecular beta-linkages, resulting in various disorders from cirrhosis to thrombosis. These provide a well defined structural prototype for the new entity of the conformational diseases, including the common dementias, as confirmed by the recent identification of the familial neuroserpin dementias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14587291     DOI: 10.1042/bss0700163

Source DB:  PubMed          Journal:  Biochem Soc Symp        ISSN: 0067-8694


  6 in total

1.  Accumulation of mutant neuroserpin precedes development of clinical symptoms in familial encephalopathy with neuroserpin inclusion bodies.

Authors:  Giovanna Galliciotti; Markus Glatzel; Jochen Kinter; Serguei V Kozlov; Paolo Cinelli; Thomas Rülicke; Peter Sonderegger
Journal:  Am J Pathol       Date:  2007-04       Impact factor: 4.307

2.  L-asparaginase-induced antithrombin type I deficiency: implications for conformational diseases.

Authors:  David Hernández-Espinosa; Antonia Miñano; Constantino Martínez; Elena Pérez-Ceballos; Inmaculada Heras; José L Fuster; Vicente Vicente; Javier Corral
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities.

Authors:  Sonia Águila; Gonzalo Izaguirre; Irene Martínez-Martínez; Vicente Vicente; Steven T Olson; Javier Corral
Journal:  J Biol Chem       Date:  2017-07-25       Impact factor: 5.157

4.  The infective polymerization of conformationally unstable antithrombin mutants may play a role in the clinical severity of antithrombin deficiency.

Authors:  Irene Martínez-Martínez; José Navarro-Fernández; Sonia Aguila; Antonia Miñano; Nataliya Bohdan; María Eugenia De La Morena-Barrio; Adriana Ordóñez; Constantino Martínez; Vicente Vicente; Javier Corral
Journal:  Mol Med       Date:  2012-07-18       Impact factor: 6.354

5.  Fluorescence correlation spectroscopic study of serpin depolymerization by computationally designed peptides.

Authors:  Pramit Chowdhury; Wei Wang; Stacey Lavender; Michelle R Bunagan; Jason W Klemke; Jia Tang; Jeffrey G Saven; Barry S Cooperman; Feng Gai
Journal:  J Mol Biol       Date:  2007-03-21       Impact factor: 5.469

6.  Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin.

Authors:  Sonia Aguila; Irene Martínez-Martínez; Gilda Dichiara; Ricardo Gutiérrez-Gallego; José Navarro-Fernández; Vicente Vicente; Javier Corral
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.